{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:50:31Z","timestamp":1792173031080,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Obesity-related problems can now be managed with effective nutritional therapy, pharmacotherapy, and surgeries that achieve &gt;10% weight loss. Assessing patient preferences, treatment choices, and factors affecting patients can improve treatment compliance and efficacy. Our aim was to identify factors affecting patient preference and subsequent choice of pharmacotherapy among those seeking treatment for obesity-related disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A participatory action study using purposeful sampling recruited 33 patients with obesity complications. They were referred to specialist clinics in non-alcoholic fatty liver disease, diabetes mellitus, hypertension, and chronic kidney disease. Sixteen males and seventeen females aged 18\u201370 years, with BMI\u2009&gt;\u200935\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      were recruited. Before the interview, participants watched a 60-minute video explaining nutritional therapy, pharmacotherapy, and surgery in equipoise. Data were collected in semi-structured interviews; Reflective thematic analysis was used. This sub study focuses only on patients who expressed specific attitudes (positive or negative) towards pharmacotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten (30%) patients expressed a view on pharmacotherapy. Eight (24%) patients chose pharmacotherapy alone, whereas two (6%) patients chose pharmacotherapy combined with nutritional therapy. In this sub study focusing on pharmacotherapy, five themes were identified related to choosing whether or not to take medication: (1) attitudes towards pharmacotherapy, (2) attitudes toward size of obesity and its complications, (3) weighing the benefits and risks of treatment, (4) knowledge and reassurance of health professionals, and (5) costs associated with drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The primary concerns regarding pharmacotherapy for intentional weight loss were efficacy, side effects, lifelong dosing, pharmacokinetics, and cost. Providing access to information about all the pharmacotherapies and the benefits is likely to result in greater penetrance of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41366-024-01524-4","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T10:48:33Z","timestamp":1714560513000},"page":"397-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Factors that determine patients considering medication for the disease of obesity: an IMI2 SOPHIA study"],"prefix":"10.1038","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7288-5245","authenticated-orcid":false,"given":"H. C.","family":"Craig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Alsaeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-4391","authenticated-orcid":false,"given":"W.","family":"Al-Najim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5006-4369","authenticated-orcid":false,"given":"E.","family":"Al Ozairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-5445","authenticated-orcid":false,"given":"C. W.","family":"le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"1524_CR1","volume-title":"WHO European Regional Obesity Report 2022","author":"World Health Organisation.","year":"2022","unstructured":"World Health Organisation. WHO European Regional Obesity Report 2022. Copenhagen: WHO; 2022."},{"key":"1524_CR2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11899-016-0333-2","volume":"11","author":"EK Tseng","year":"2016","unstructured":"Tseng EK, Hicks LK. Value based care and patient-centered care: divergent or complementary? Curr Hematol Malignancy Rep. 2016;11:303\u201310.","journal-title":"Curr Hematol Malignancy Rep."},{"key":"1524_CR3","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/bmj.39372.540903.94","volume":"335","author":"A Kennedy","year":"2007","unstructured":"Kennedy A, Rogers A, Bower P. Support for self care for patients with chronic disease. BMJ. 2007;335:968\u201370.","journal-title":"BMJ"},{"key":"1524_CR4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.12927\/hcpap.2019.26031","volume":"18","author":"K Gilmore","year":"2019","unstructured":"Gilmore K, Pennucci F, De Rosis S, Passino C. Value in healthcare and the role of the patient voice. HealthcarePapers. 2019;18:28\u201335.","journal-title":"HealthcarePapers"},{"key":"1524_CR5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"19","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;19:613\u201326.","journal-title":"Lancet"},{"key":"1524_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5001\/omj.2011.38","volume":"26","author":"B Beena","year":"2011","unstructured":"Beena B, Jimmy J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26:155\u20139.","journal-title":"Oman Med J"},{"key":"1524_CR7","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3390\/pharmaceutics13071100","volume":"13","author":"K Kvarnstr\u00f6m","year":"2021","unstructured":"Kvarnstr\u00f6m K, Westerholm A, Airaksinen M, Liira H. Factors contributing to medication adherence in patients with a chronic condition: a scoping review of qualitative research. Pharmaceutics. 2021;13:1100.","journal-title":"Pharmaceutics"},{"key":"1524_CR8","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1007\/s12325-016-0394-6","volume":"33","author":"N Pag\u00e8s-Puigdemont","year":"2016","unstructured":"Pag\u00e8s-Puigdemont N, Mangues M, Masip M, Gabriele G, Fern\u00e1ndez-Maldonado L, Blancafort S, et al. Patients\u2019 perspective of medication adherence in chronic conditions: a qualitative study. Adv Ther. 2016;33:1740\u201354.","journal-title":"Adv Ther"},{"key":"1524_CR9","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1002\/osp4.720","volume":"10","author":"HC Craig","year":"2023","unstructured":"Craig HC, Alsaeed D, Norris S, Holian J, Kennedy C, Feldman A, et al. Patient perspectives about treatment preferences for obesity with complications. Obes Sci Pract. 2023;10:e720.","journal-title":"Obes Sci Pract"},{"key":"1524_CR10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0277-9536(03)00259-4","volume":"58","author":"P Bissell","year":"2004","unstructured":"Bissell P, May CR, Noyce PR. From compliance to concordance: barriers to accomplishing a re-framed model of health care interactions. Soc Sci Med. 2004;58:851\u201362.","journal-title":"Soc Sci Med"},{"key":"1524_CR11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1748-0361.2006.00059.x","volume":"22","author":"AC Ely","year":"2006","unstructured":"Ely AC, Greiner KA, Born W, Hall S, Rhode PC, James AS, et al. Concordance of patient-physician obesity diagnosis and treatment beliefs in rural practice settings. J Rural Health. 2006;22:364\u20136.","journal-title":"J Rural Health"},{"key":"1524_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10912-007-9030-4","volume":"28","author":"JZ Segal","year":"2007","unstructured":"Segal JZ. \u201cCompliance\u201d to \u201cConcordance\u201d: a critical view. J Med Humanities. 2007;28:81\u201396.","journal-title":"J Med Humanities"},{"key":"1524_CR13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s13300-021-01178-9","volume":"13","author":"F G\u00f3mez-Peralta","year":"2022","unstructured":"G\u00f3mez-Peralta F, Mareque M, Mu\u00f1oz \u00c1, Maderuelo M, Casado M\u00c1. Patient preferences for pharmacological diabetes treatment among people with diabetes in spain: a discrete choice experiment. Diabetes Ther. 2022;13:75\u201387.","journal-title":"Diabetes Ther"},{"key":"1524_CR14","first-page":"PA356","volume":"17","author":"AC M\u00fchlbacher","year":"2014","unstructured":"M\u00fchlbacher AC, Kaczynski A. Patient preferences in treatment of diabetes mellitus: a systematic review of stated preference surveys. ISPOR. 2014;17:PA356.","journal-title":"ISPOR"},{"key":"1524_CR15","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2147\/PPA.S388356","volume":"16","author":"X Xu","year":"2022","unstructured":"Xu X, Guo T, Liu Z, Chen P, Zhang Y, Ji Q, et al. A systematic review of patient preferences, expectations, and values for the management and treatment of hypertension. patient prefer adherence. a systematic review of patient preferences, expectations, and values for the management and treatment of hypertension. Patient Prefer Adherence. 2022;16:2867\u201376.","journal-title":"Patient Prefer Adherence"},{"key":"1524_CR16","doi-asserted-by":"crossref","unstructured":"Dey I Grounding grounded theory: Guidelines for qualitative inquiry. 1999 Press A, editor. San Diego:: Academic Press; 282 p.","DOI":"10.1016\/B978-012214640-4\/50011-5"},{"key":"1524_CR17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/2159676X.2019.1704846","volume":"13","author":"V Braun","year":"2021","unstructured":"Braun V, Clarke V. To saturate or not to saturate? Questioning data saturation as a useful concept for thematic analysis and sample-size rationales. Qualit Res Sport, Exerc Health. 2021;13:201\u201316.","journal-title":"Qualit Res Sport, Exerc Health"},{"key":"1524_CR18","first-page":"1408","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? data saturation in qualitative research. Qualit Rep. 2015;20:1408\u201316.","journal-title":"Qualit Rep."},{"key":"1524_CR19","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(21)00377-9","volume":"397","author":"R Latini","year":"2021","unstructured":"Latini R, Staszewsky L. Semaglutide and effective weight control. Lancet. 2021;397:942\u20133.","journal-title":"Lancet"},{"key":"1524_CR20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971\u201384.","journal-title":"Lancet"},{"key":"1524_CR21","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403\u201313.","journal-title":"JAMA"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01524-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01524-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01524-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:43:21Z","timestamp":1743817401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-024-01524-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1524"],"URL":"https:\/\/doi.org\/10.1038\/s41366-024-01524-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3789071\/v1","asserted-by":"object"}]},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HCC, Part funding of PhD tuition fees from the Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (SOPHIA) project (\n                      \n                      ). WAl-N\u2014no conflict of interest. DA\u2014no conflict of interest. HH\u2014no conflict of interest. EAO\u2014no conflict of interest, CWlR: Consulting fees\/Honoria\/Support for meetings: NovoNordisk, Eli Lilly, Johnson & Johnson, Boehringer Ingelheim, GI Dynamics, Herbalife. Leadership\/fiduciary role in Board: Irish Society for Nutrition and Metabolism (unpaid). Stock Options: Keyron Previous Chief medical officer and Director of the Medical Device Division of Keyron in 2011. Both of these were unremunerated positions. Previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. He continues to provide scientific advice to Keyron for no remuneration.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}